Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M
With the deal, Lilly can use Camurus' long-acting delivery technology on up to four of its own incretin compounds to develop injections in the cardiometabolic health space.
With the deal, Lilly can use Camurus' long-acting delivery technology on up to four of its own incretin compounds to develop injections in the cardiometabolic health space.
